Search research articles
Contact Us
Filters
Showing results (11-20 of 210) with videos related to
Page
of 21
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 20, 2016
Integration of Telemedicine Into Clinical Gastroenterology and Hepatology Practice
Raymond K Cross, Sunanda Kane
Expert Opinion on Drug Safety
|
July 4, 2015
Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
Matilda Hagan, Raymond K Cross
Digestive Diseases and Sciences
|
January 11, 2007
Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study
Raymond K Cross, Joseph Finkelstein
Expert Opinion on Emerging Drugs
|
November 12, 2022
Emerging drugs for the treatment of inflammatory bowel disease
Uni Wong, Raymond K Cross
Gastroenterology & Hepatology
|
April 29, 2024
Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences
Preetika Sinh, Raymond K Cross
Southern Medical Journal
|
March 28, 2003
Two cases of spontaneous epidural abscess in patients with cirrhosis
Raymond K Cross, Charles Howell
Inflammatory Bowel Diseases
|
January 17, 2020
Are Inflammatory Bowel Disease Patients With Diabetes Mellitus at Increased Risk for Poor Outcomes Including Greater Health Care Utilization?
Uni Wong, Raymond K Cross
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 24, 2018
Improving Outcomes in Patients With Inflammatory Bowel Disease Through Integrated Multi-Disciplinary Care-the Future of IBD Care
Kaci Christian, Raymond K Cross
Expert Opinion on Drug Metabolism & Toxicology
|
September 7, 2017
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Uni Wong, Raymond K Cross
Expert Opinion on Investigational Drugs
|
March 19, 2019
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
Uni Wong, Raymond K Cross
Page
of 21
Search research articles
Search
Showing results (11-20 of 210) with videos related to
Sort By:
Page
of 21
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 20, 2016
Integration of Telemedicine Into Clinical Gastroenterology and Hepatology Practice
Raymond K Cross, Sunanda Kane
Expert Opinion on Drug Safety
|
July 4, 2015
Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
Matilda Hagan, Raymond K Cross
Digestive Diseases and Sciences
|
January 11, 2007
Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study
Raymond K Cross, Joseph Finkelstein
Expert Opinion on Emerging Drugs
|
November 12, 2022
Emerging drugs for the treatment of inflammatory bowel disease
Uni Wong, Raymond K Cross
Gastroenterology & Hepatology
|
April 29, 2024
Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences
Preetika Sinh, Raymond K Cross
Southern Medical Journal
|
March 28, 2003
Two cases of spontaneous epidural abscess in patients with cirrhosis
Raymond K Cross, Charles Howell
Inflammatory Bowel Diseases
|
January 17, 2020
Are Inflammatory Bowel Disease Patients With Diabetes Mellitus at Increased Risk for Poor Outcomes Including Greater Health Care Utilization?
Uni Wong, Raymond K Cross
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 24, 2018
Improving Outcomes in Patients With Inflammatory Bowel Disease Through Integrated Multi-Disciplinary Care-the Future of IBD Care
Kaci Christian, Raymond K Cross
Expert Opinion on Drug Metabolism & Toxicology
|
September 7, 2017
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Uni Wong, Raymond K Cross
Expert Opinion on Investigational Drugs
|
March 19, 2019
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
Uni Wong, Raymond K Cross
Page
of 21